NOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.

Similar documents
Children Enteric coated tablet : 1-3 mg/kg per day in divided doses.

Action Rufenal contains a non - steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties.

MESULID 100 REVISED PRODUCT INFORMATION

PRODUCT INFORMATION Panadeine EXTRA

NEW ZEALAND DATASHEET

PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

TERICOX. Composition Each film-coated tablet contains 60, 90, or 120 mg of Etoricoxib.

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

PROFESSIONAL INFORMATION

Action Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed than Naproxen.

SUMMARY OF PRODUCT CHARACTERISTICS

NEW ZEALAND DATA SHEET

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

DATA SHEET. PANADOL Mini Caps Capsule shaped tablet with a gelatin coating which is one half green and the other half white.

PANADOL EXTRA PRODUCT INFORMATION

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed

patient group direction

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

Summary of Product Characteristics

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.

Metabolism Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.

PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION

PRODUCT INFORMATION LEAFLET

Non-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6

AUSTRALIAN PRODUCT INFORMATION PANADOL OPTIZORB TABLETS (PARACETAMOL) TABLETS PANADOL OPTIZORB CAPLETS (PARACETAMOL) TABLETS

CSP Nabumetone ES/H/PSUR/0014/001. January 2010

NEW ZEALAND DATA SHEET

Summary of Product Characteristics

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

SUMMARY OF PRODUCT CHARACTERISTICS

Elements for a Public Summary Overview of disease epidemiology

PANADOL OSTEO PRODUCT INFORMATION

Elements for a Public Summary

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

DATA SHEET. Paracetamol (BP) 500 mg and Phenylephrine Hydrochloride (BP) 5 mg

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

NEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 200 mg of ibuprofen.

NAPREX. Composition Naprex Suppositories Each suppository contains Naproxen 500 mg.

SUMMARY OF PRODUCT CHARACTERISTICS

Each 5ml of Sinarest LP New Syrup contains: Phenylephrine

Etopan XL 600 mg tablets

Name Brufen Flu Tablets & Suspension Description For the relief of the symptoms of colds and flu. Active Ingredients:

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1

Diclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

PARACOD Tablets (Paracetamol + Codeine phosphate)

LEAFLET: INFORMATION FOR THE USER. Freshalgin 500th mg tablets Metamizole sodium (M etamizol sodium)

SUMMARY OF PRODUCT CHARACTERISTICS

AROMASIN 25mg (Tablets)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Package Insert. Spasfree

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic

Ibuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN

PRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol)

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

patient group direction

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Salicylates: Interactions 10/14/2009. Salicylates DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS. Chapters 17, 18, 34 & Pages 577 &

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

M0BCore Safety Profile

4 2 Osteoarthritis 1

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS

disease or in clients who consume alcohol on a regular basis. bilirubin

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

Please note that the information highlighted in grey colour is the additional information specific to the concerned dosage form.

CHILDREN S PANADOL COLOURFREE SUSPENSION PANADOL SUPPOSITORIES 125 MG PANADOL SUPPOSITORIES 250 MG DATA SHEET. Proprietary (Trade) Name: PANADOL

INSTRUCTION for medical use DICLOTOL

Summary of Product Characteristics Updated 01-May-2015 Meda Pharmaceuticals

NEOFEN 60 mg suppository

ART 50 Capsules. Symptomatic treatment of functional symptoms and signs of osteoarthritis.

Drugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

ETORICOXIB ARCOXIA TM / ARCOXIA TM Ac

NONSTEROIDAL ANTI- INFLAMMATORY DRUGS

New Zealand Datasheet

Bristol Laboratories Limited

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

INSPRA 25 & 50 mg TABLETS

APPROVED PACKAGE INSERT

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

DATA SHEET. Product Summary. 1. Trade Name of Medicinal Product. Protamine Sulphate Injection BP. 2. Qualitative and Quantitative Composition

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION

Transcription:

NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation through a variety of mechanisms and in addition exerts stimulatory effects on cartilage matrix synthesis. Anti-inflammatory activity: the anti-inflammatory effects of Diclofenac have been shown in both acute and chronic inflammation. It inhibits various mediators of pain and inflammation including: PGE2 via cyclooxygenase inhibition (COX-1 & COX-2) after intracellular metabolism to 4 hydroxy-aceclofenac and diclofenac in human rheumatoid synovial cells and other inflammatory cells. IL-IB, IL-6 and tumor necrosis factor in human osteoarthritic synovial cells and human articular chondrocytes. Reactive oxygen species (which plays a role in joint damage) has also been observed in patients with osteoarthritis of knee. Expression of cell adhesion molecules (which is implicated in cell migration and inflammation) has also been shown in human neutrophils.

Stimulatory effects on cartilage matrix synthesis: Diclofenac stimulates glycosaminoglycan synthesis in human osteoarthritis cartilage by inhibition of IL-1B and suppresses cartilage degeneration by inhibiting IL-IB mediated pro-matrix metalloproteinase production and proteoglycan release. Paracetamol is a clinically proven analgesic and antipyretic agent with a weak anti-inflammatory effect. Analgesic action: The central analgesic action of paracetamol resembles that of aspirin. It produces analgesia by raising pain threshold. Antipyretic effects: The antipyretic effect of paracetamol is attributed as its ability to inhibit COX in the brain where peroxide tone is low. Recent evidence suggests inhibition of COX-3 (believed to be splice varient product of the COX-1 gene) could represent primary central mechanism by which paracetamol decreases pain and possibly fever. Pharmacokinetics Paracetamol is rapidly and almost completely absorbed from gastrointestinal tract with peak plasma concentrations (Cmax) occurring about 10 to 60 minutes after oral administration. Plasma protein binding is negligible at usual therapeutic concentration but increases with increase concentrations. Paracetamol is relatively uniformly distributed throughout most body fluids. The plasma half-life (t1/2) 2-3 hours and the effect after oral dose lasts for 3-5 hours. Paracetamol is metabolized predominantly in liver and excreted in the urine mainly as glucuronide and sulphate conjugate. Less than 5% is excreted unchanged.

Diclofenac is 100% absorbed after oral administration compared to IV administration as measured by urine recovery. However, due to firstpass metabolism, only about 50% of the absorbed dose is systematically available. In some fasting normal volunteers, measurable plasma levels are observed within 10 minutes of dosing with Diclofenac. Peak plasma levels are achieved approximately 1hours in fasting normal volunteers, with a range of 33 minutes to 2hours. Food has no significant effect on the extent of diclofenac absorption and a reduction in peak plasma levels of approximately 30%. Mechanism of Action Diclofenac sodium caplets are a non-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action of diclofenac sodium caplets, like that of other NSAIDs is not completely understood but may be related to prostaglandin synthetase inhibition. Paracetamol has analgesic and antipyretic actions. Rationale of Combination of Diclofenac Sodium & Paracetamol Diclofenac is a time tested prompt acting analgesic with anti-inflammatory actions, Paracetamol is a time tested antipyretic with analgesic & anti-inflammatory actions. This medicine contains time tested analgesic, antioyretic with both having anti-inflammatory actions too. Indications Notopain is indicated for relief from severe pain and inflammation in Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis. Low back pain, Dental pain, Gynaecological pain, painful & Inflammatory conditions of ear, nose & throat. Dosage and Administration

The maximum recommended dose of NOTOPAIN is two caplets daily, as one caplet in the morning and one in the evening. Contraindications Patients sensitive to paracetamol or to any of the excipients of the product Patients in whom aspirin or other NSAIDs precipitate attacks of bronchospasm, acute rhinitis or urticaria or patients hypersensitive to these drugs. Patients with active or suspected peptic ulcer or gastrointestinal bleeding or bleeding disorders Patients with severe heart failure, hypertension, hepatic or renal insufficiency, Third trimester of pregnancy Warning and precautions This medicine may cause dizziness. Driving or operating machinery are to be avoided. Individual receiving long-term treatments should be regularly monitored for renal function tests, liver function tests and blood counts. It is to be used with caution in hepatic porphyria, coagulation disorders, history of peptic ulcers, ulcerative colitis, Cohn s disease, SLE, cerebrovascular bleeding, pregnancy and lactation. Caution should be exercised in patients with mild to moderate impairment of cardiac, hepatic or renal function and in elderly patients who are likely to be suffering from these conditions. Caution is also required in patients on diuretic therapy or otherwise at risk of hypovolemia. Drug Interactions Drug interactions associated with Paracetamol are similar to those observed with other NSAIDs. Paracetamol may increase the plasma

concentrations in lithium, digoxin and methotrexate. It may increase the activity of anticoagulants, inhibits the activity of diuretics, enhances, cyclosporine nehrotoxicity and precipitate convulsions when co administered with quinolone antibiotics, Co administration of Paracetamol with other NSAIDs and corticosteroids are to be avoided due to increased incidence of side effects. The risk of Paracetamol toxicity may be increased in patients receiving other potentiality heatotoxic drugs or drugs that induce hepatic microsomal enzymes. Cpadministration of Paracetamol with rifampicin, Isoniazid, Chlorarnphenicol, antiepileptic drugs and antiviral drugs is to be avoided. Metoclopromide may increase the absorption of Paracetamol whereas excretion and plasma concentration may be altered when co administered with probenecid. Choiestyramine also reduces the absorption of Paracetamol. Over dosage Over dosage may cause nausea, vomiting, pain abdomen, dizziness, somnolence, headache, sweating, pancreatitis, hepatic failure and acute renal failure, Treatment, if required includes gatric lavage, activated charcoal and other symptomatic measures as per medical advice. Storage Store in an airtight container, protect from light Presentation: 10 caplets in Blister pack Keep medicine out of reach of children